[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![NighthawkTradez Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::1874923743690051584.png) NightHawk Capital [@NighthawkTradez](/creator/twitter/NighthawkTradez) on x 3932 followers
Created: 2025-07-23 23:11:47 UTC

This isn’t just about more GLP-1 supply.

If 503Bs are truly ramping and HHS or FDA steps in, it means:

• Compounding becomes legally protected
• Patent lawsuits from Novo and Lilly become irrelevant
• Pricing power shifts to platforms like Hims
• Margins expand without branded drug costs
• Nationwide distribution becomes instantly viable

This turns $HIMS from a telehealth brand into a fully integrated GLP-1 engine.

🤯🤯🤯🤯🤯🤯🤯🤯🤯🤯


XXXXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1948159135855296842/c:line.svg)

**Related Topics**
[telehealth](/topic/telehealth)
[$hims](/topic/$hims)
[hims](/topic/hims)
[novo](/topic/novo)
[hims hers](/topic/hims-hers)
[stocks consumer defensive](/topic/stocks-consumer-defensive)

[Post Link](https://x.com/NighthawkTradez/status/1948159135855296842)